The impact of TP53 mutations is so significant that authors such as Grimwade and Papaemmanuil consider that mutations in this gene can be regarded as a driver in the leukemogenesis process in a subgroup of AML patients [1,34]. This evidence concerns the gene TP53 and acute myeloid leukemia.